United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2014_register executive 2014-07-16 article Notices D09002ee1c7f9196a D09002ee1c7f91a04 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to practice the inventions embodied in U.S. Provisional Patent Application. No. 61/250,601, filed October 12, 2009, HHS Ref. No.: E-158-2009/0-US-01, Titled: "Granulysin Immunotherapy"; International Application No. PCT/US2010/052036, filed October 8, 2010, HHS Ref. No.: E-158-2009/0-PCT-02, Titled: "Granulysin Immunotherapy"; U.S. Patent Application No. 13/501,726, filed April 12, 2012, HHS Ref. No.: E-158-2009/0-US-06, Titled: "Granulysin Immunotherapy", and foreign equivalents thereof to Orpheden Therapeutics, Inc. ("Orpheden"), a Delaware corporation doing business principally in the state of Illinois. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive evaluation option license territory may be worldwide and the field of use may be limited to the development of 15kD granulysin as set forth in the Licensed Patent Rights for the treatment of human cancers. Upon the expiration or termination of the exclusive evaluation option license, Orpheden will have the exclusive right to execute an exclusive commercialization license which will supersede and replace the exclusive evaluation option license with no greater field of use and territory than granted in the exclusive evaluation option license. 79 FR 40118 https://www.govinfo.gov/app/details/FR-2014-07-11/2014-16267 2014-16267 fr11jy14-88 4140-01-P https://www.govinfo.gov/app/details/FR-2014-07-11/2014-16267 https://www.govinfo.gov/content/pkg/FR-2014-07-11/html/2014-16267.htm https://www.govinfo.gov/content/pkg/FR-2014-07-11/pdf/2014-16267.pdf 2 p. 40118 40119 79 FR 40118 Prospective Grant of Evaluation Option Exclusive License: Development of Granulysin Immunotherapy; Federal Register Vol. 79, Issue NOTICE 2014-16267 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2014-07-28 4140-01-P 2014-16267 Notice.

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to practice the inventions embodied in U.S. Provisional Patent Application. No. 61/250,601, filed October 12, 2009, HHS Ref. No.: E-158-2009/0-US-01, Titled: "Granulysin Immunotherapy"; International Application No. PCT/US2010/052036, filed October 8, 2010, HHS Ref. No.: E-158-2009/0-PCT-02, Titled: "Granulysin Immunotherapy"; U.S. Patent Application No. 13/501,726, filed April 12, 2012, HHS Ref. No.: E-158-2009/0-US-06, Titled: "Granulysin Immunotherapy", and foreign equivalents thereof to Orpheden Therapeutics, Inc. ("Orpheden"), a Delaware corporation doing business principally in the state of Illinois. The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive evaluation option license territory may be worldwide and the field of use may be limited to the development of 15kD granulysin as set forth in the Licensed Patent Rights for the treatment of human cancers. Upon the expiration or termination of the exclusive evaluation option license, Orpheden will have the exclusive right to execute an exclusive commercialization license which will supersede and replace the exclusive evaluation option license with no greater field of use and territory than granted in the exclusive evaluation option license.

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 28, 2014 will be considered. Exclusive Licenses: Development of Granulysin Immunotherapy , hastingw@mail.nih.gov Vol. 79, no. 133 Office of the Federal Register, National Archives and Records Administration 2014-07-11 continuing daily deposited born digital 675 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2014-07-11 P0b002ee18985e1cf 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr11jy14 https://www.govinfo.gov/app/details/FR-2014-07-11 https://www.govinfo.gov/content/pkg/FR-2014-07-11/pdf/FR-2014-07-11.pdf https://www.govinfo.gov/content/pkg/FR-2014-07-11/xml/FR-2014-07-11.xml fdlp 39953 40618 DGPO 2014-07-16 2024-06-02 FR-2014-07-11 machine generated eng FR FR-2014-07-11 79 133